REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.

Kazuomi Ueshima,Masatoshi Kudo,Takeharu Yamanaka,Hiroshi Aikata,Tatsuya Yamashita,Masafumi Ikeda,Ryosuke Tateishi,Michihisa Moriguchi,Atsushi Hiraoka,Kaoru Tsuchiya,Sadahisa Ogasawara,Satoshi Mochida,Shiro Miyayama,Kiyoshi Hasegawa,Kenichi Yoshimura,Tetsuo Takehara

REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.

2021

Kazuomi Ueshima
Masatoshi Kudo
Takeharu Yamanaka
Hiroshi Aikata
Tatsuya Yamashita
Masafumi Ikeda
Ryosuke Tateishi
Michihisa Moriguchi
Atsushi Hiraoka
Kaoru Tsuchiya
Sadahisa Ogasawara
Satoshi Mochida
Shiro Miyayama
Kiyoshi Hasegawa
Kenichi Yoshimura
Tetsuo Takehara

TPS4162Background: Transarterial chemoembolization (TACE) had been developed as a standard of care in patients with intermediate-stage HCC at a time when systemic therapy was not available. This st...

Keywords:

in patient
Bevacizumab
intermediate stage
Systemic therapy
Internal medicine
Medicine
Oncology
Hepatocellular carcinoma
Atezolizumab
Combination therapy
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations